Suppr超能文献

毛霉菌病:来自黎巴嫩一家三级医疗中心的14年回顾性研究。

Mucormycosis: A 14-Year Retrospective Study from a Tertiary Care Center in Lebanon.

作者信息

Allaw Fatima, Zakhour Johnny, Nahhal Sarah B, Koussa Karim, Bitar Elio R, Ghanem Anthony, Elbejjani Martine, Kanj Souha S

机构信息

Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, Beirut 110236, Lebanon.

Faculty of Medicine, American University of Beirut, Beirut 110236, Lebanon.

出版信息

J Fungi (Basel). 2023 Aug 3;9(8):824. doi: 10.3390/jof9080824.

Abstract

Mucormycosis (MCM) is a serious invasive fungal disease (IFD) that is associated with high mortality, particularly in immunocompromised patients. A global surge in MCM cases was reported with the COVID-19 pandemic. We analyzed all recorded cases of MCM at the American University of Beirut Medical Center (AUBMC), a tertiary care center in Lebanon, over 14 years. We aimed to identify the incidence, seasonal variation, clinical characteristics of the patients, and predictors of mortality. We conducted a retrospective chart review between 1 January 2008 and 1 January 2023. All patients with proven or probable MCM were included in the study. Proven or probable MCM was defined by positive histopathology and/or positive cultures. A total of 43 patients were identified as having MCM. Their median age was 53 years, and the majority were males (58.1%). Most of the cases were diagnosed in the autumn season. In total, 67.4% of the patients had hematological malignancies (HMs), and 34.9% had uncontrolled diabetes mellitus (DM). The most common site of involvement was rhino-orbital-cerebral MCM (ROCM) (74%). The annual cases of MCM per 100,000 patient days increased markedly during the years of the COVID-19 pandemic (from 0 to 4.4 cases/100,000 patient days to 7.5 cases/100,000 during 2020 and 2021). Liposomal amphotericin (Ampho) B was used as a first-line agent in most of the patients (86%). The median duration of total in-hospital antifungal therapy was 21 days and 51.2% of the patients received step-down therapy with azoles. Surgical debridement and isolated ROCM were significantly associated with survival (-value: 0.02 and <0.001, respectively). All-cause mortality was 46.7%, with chronic renal disease being significantly associated with mortality (-value < 0.05). The incidence of MCM has been increasing at our institution, particularly since the COVID-19 pandemic. Early diagnosis, treatment, and surgical debridement improve patient outcomes and overall survival.

摘要

毛霉病(MCM)是一种严重的侵袭性真菌病(IFD),与高死亡率相关,尤其是在免疫功能低下的患者中。据报道,随着新冠疫情的爆发,全球MCM病例激增。我们分析了黎巴嫩一家三级医疗中心——贝鲁特美国大学医疗中心(AUBMC)在14年期间记录的所有MCM病例。我们旨在确定发病率、季节变化、患者的临床特征以及死亡率的预测因素。我们在2008年1月1日至2023年1月1日期间进行了一项回顾性病历审查。所有确诊或疑似MCM的患者均纳入研究。确诊或疑似MCM由组织病理学阳性和/或培养阳性定义。共有43例患者被确诊为患有MCM。他们的中位年龄为53岁,大多数为男性(58.1%)。大多数病例在秋季被诊断出来。总体而言,67.4%的患者患有血液系统恶性肿瘤(HMs),34.9%的患者患有未控制的糖尿病(DM)。最常见的受累部位是鼻眶脑型毛霉病(ROCM)(74%)。在新冠疫情期间,每10万患者日的MCM年病例数显著增加(从0至4.4例/10万患者日增加到2020年和2021年的7.5例/10万)。大多数患者(86%)使用脂质体两性霉素B作为一线药物。住院期间抗真菌治疗的总中位持续时间为21天,51.2%的患者接受了唑类药物的降阶梯治疗。手术清创和孤立性ROCM与生存率显著相关(分别为P值:0.02和<0.001)。全因死亡率为46.7%,慢性肾病与死亡率显著相关(P值<0.05)。我院MCM的发病率一直在上升,尤其是自新冠疫情以来。早期诊断、治疗和手术清创可改善患者预后和总体生存率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验